Overview

A Study to Evaluate the Effects and Safety of Hydroxocobalamin in Participants With Combined Methylmalonic Academia (cblC Type)

Status:
NOT_YET_RECRUITING
Trial end date:
2027-04-28
Target enrollment:
Participant gender:
Summary
This study is a Single-Center, Single-Arm, open-label, Phase III clinical study to evaluate the efficacy, safety characteristics of Hydroxocobalamin Chloride Injection (20 mg/mL) for Maintenance Therapy in participants with Methylmalonic Acidemia (MMA) with Elevated Homocysteine (Cobalamin C Deficiency).
Phase:
PHASE3
Details
Lead Sponsor:
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.